Gilead and Teva defend HIV drug antitrust claims; Illumina holds off broader challenge

Taking stock of the drug industry, from the lab to the medicine chest

May 25, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Justin Sullivan/Getty Images STAT+ | Gilead and Teva defend antitrust claims that prices for HIV medicines were unfairly kept high AIDS activists hope that a federal trial will help explain why HIV prevention pill Truvada has often struggled to gain uptake. By Ed Silverman Opinion: Adopting the term 'preaddiction' would be a serious mistake Instead of creating new labels, it would be more effective to take a public health approach to conceptualizing addiction. By Cassandra L. Boness STAT+ | Illumina shareholders elect one Icahn ally to board, as company holds off broader challenge Shareholders in Illumina, the DNA-sequencing firm, rejected a bid to oust other directors, including CEO Francis deSouza. By Matthew Herper Power to the Patients STAT+ | With Fat Joe concerts and Super Bowl ads, a cadre of billionaires is mounting an unorthodox campaign against hospitals A small club of billionaires is using unorthodox tactics — and piles of cash and connections — to campaign to rein in hospital prices. By Rachel Cohrs

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser